KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Non-Current Deffered Revenue (2019 - 2025)

Teladoc Health's Non-Current Deffered Revenue history spans 7 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 6.61% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, down 6.61%, while the annual FY2025 figure was $9.1 million, 6.61% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $9.1 million at Teladoc Health, down from $11.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $15.0 million in Q1 2024 and bottomed at $2.7 million in Q1 2021.
  • The 5-year median for Non-Current Deffered Revenue is $10.0 million (2024), against an average of $8.4 million.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 322.18% in 2023 before it tumbled 31.7% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $3.8 million in 2021, then surged by 211.79% to $12.0 million in 2022, then increased by 13.96% to $13.6 million in 2023, then fell by 28.17% to $9.8 million in 2024, then fell by 6.61% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Non-Current Deffered Revenue are $9.1 million (Q4 2025), $11.2 million (Q3 2025), and $10.7 million (Q2 2025).